Clicky

Horizon Pharma, Inc.(HZNP)

Description: Horizon Pharma, Inc., a specialty pharmaceutical company, through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. The company offers DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications. It also provides LODOTRA/RAYOS, a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe active rheumatoid arthritis in adults when accompanied by morning stiffness, as well as approved for the treatment of polymyalgia rheumatica, psoriatic arthritis, ankylosing spondylitis, asthma, chronic obstructive pulmonary disease, and other conditions. The company was founded in 2005 and is headquartered in Deerfield, Illinois.


Keywords: Medicine Pharmaceutical Pain Autoimmune Disease Rheumatoid Arthritis Arthritis Asthma Inflammatory Diseases Osteoarthritis Ulcer Chronic Obstructive Pulmonary Disease Gastrointestinal Rheumatology Pulmonary Disease Psoriatic Arthritis Spondylitis Ankylosing Spondylitis Rheumatism Ibuprofen Severe Active Rheumatoid Arthritis

Home Page: www.horizontherapeutics.com

HZNP Technical Analysis

70 St. Stephen’s Green
Dublin, 2
Ireland
Phone: 353 1 772 2100


Officers

Name Title
Mr. Timothy P. Walbert Chairman, Pres & CEO
Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D. Exec. VP & Chief Medical Officer
Mr. Paul W. Hoelscher Advisor
Mr. Andy Pasternak Exec. VP & Chief Strategy Officer
Mr. Aaron L. Cox Exec. VP of Fin. & CFO
Mr. Patrick McIlvenny Sr. VP & Chief Accounting Officer
Ms. Tina E. Ventura Sr. VP & Chief Investor Relations Officer
Mr. Sean M. Clayton J.D. Exec. VP & Gen. Counsel
Mr. Geoffrey M. Curtis Exec. VP of Corp. Affairs & Chief Communications Officer
Ms. Jane Gonnerman Sr. VP of Corp. Devel. & Chief of Staff, Office of the CEO

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 21.7391
Trailing PE: 46.5473
Price-to-Book MRQ: 5.1009
Price-to-Sales TTM: 6.9288
IPO Date: 2011-07-28
Fiscal Year End: December
Full Time Employees: 2095
Back to stocks